AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
• An advanced and user-friendly organoid culture methodology
• Consistent genome stability and gene expression profiles throughout the culture process
• Potential for high-throughput drug screening without reliance on matrigel
Intrahepatic cholangiocarcinoma (ICC) is a highly lethal malignancy associated with significant morbidity, necessitating the urgent development of an effective chemotherapeutic assay for ICC patients. In this study, we have successfully established an advanced culture method for ICC organoids that can be utilized with both single-cell assembly and tissue fragmentation initiation techniques. These ICC organoids maintain the morphological characteristics, including mutation profiles and frequency (46.9% in organoid and 48.5% in tumor tissue) of IDH1 genes, and 1733 high-frequent overlapped mutated genes (94.2%). Additionally, ICC biomarkers such as CK7 and CK19 also maintain a similar pattern compared with the original tissue. Furthermore, RNA-seq analysis reveals upregulation of immune-related genes in single-cell assembly organoids. The significantly changed genes including IL9R (4.4-fold), IL2RB (3.2-fold), CCR4 (3.5-fold), TESPA1 (4.4-fold), ZAP70 (4.3-fold) and CD6 (4.3-fold) in log scale. These evidence both indicating the presence of viable and active immune cells. Overall, our findings present an advanced and user-friendly culture approach for generating ICC organoids adaptable to diverse experimental objectives.
Yao, K. J., Jabbour, S., Parekh, N., Lin, Y., Moss, R. A. Increasing mortality in the United States from cholangiocarcinoma: An analysis of the National Center for Health Statistics Database. BMC Gastroenterology, 2016, 16(1): 117. https://doi.org/10.1186/s12876-016-0527-z
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y., Zhu, A. X. Biliary tract cancer. The Lancet, 2021, 397(10272): 428–444. https://doi.org/10.1016/s0140-6736(21)00153-7
El-Diwany, R., Pawlik, T. M., Ejaz, A. Intrahepatic cholangiocarcinoma. Surgical Oncology Clinics of North America, 2019, 28(4): 587–599. https://doi.org/10.1016/j.soc.2019.06.002
Benson, A. B., D’Angelica, M. I., Abrams, T. A., Are, C., Bloomston, P. M., Chang, D. T., Clary, B. M., Covey, A. M., Ensminger, W. D., Iyer, R. et al. Hepatobiliary cancers, version 2.2014. Official Journal of the National Comprehensive Cancer Network, 2014, 12(8): 1152–1182. https://doi.org/10.6004/jnccn.2014.0112
Rizzo, A., Ricci, A. D., Brandi, G. Durvalumab: An investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30(4): 343–350. https://doi.org/10.1080/13543784.2021.1897102
Oh, D. Y., Lee, K. H., Lee, D. W., Yoon, J., Kim, T. Y., Bang, J. H., Nam, A. R., Oh, K. S., Kim, J. M., Lee, Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study. The Lancet Gastroenterology & Hepatology, 2022, 7(6): 522–532. https://doi.org/10.1016/s2468-1253(22)00043-7
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W. et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34(2): 127–140. https://doi.org/10.1016/j.annonc.2022.10.506
Wang, Z. W., Jin, Y., Guo, Y. H., Tan, Z. H., Zhang, X. X., Ye, D., Yu, Y. Q., Peng, S. Y., Zheng, L., Li, J. T. Conversion therapy of intrahepatic cholangiocarcinoma is associated with improved prognosis and verified by a case of patient-derived organoid. Cancers, 2021, 13(5): 1179. https://doi.org/10.3390/cancers13051179
Wang, Z. W., Guo, Y. H., Jin, Y., Zhang, X. X., Geng, H., Xie, G. Y., Ye, D., Yu, Y. Q., Liu, D. R., Zhou, D. E. et al. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids. Cancer Cell International, 2021, 21(1): 519. https://doi.org/10.1186/s12935-021-02219-w
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P. et al. Human primary liver cancer–derived organoid cultures for disease modeling and drug screening. Nature Medicine, 2017, 23(12): 1424–1435. https://doi.org/10.1038/nm.4438
Liu, L. Z., Yang, L. X., Zheng, B. H., Dong, P. P., Liu, X. Y., Wang, Z. C., Zhou, J., Fan, J., Wang, X. Y., Gao, Q. CK7/CK19 index: A potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. Journal of Surgical Oncology, 2018, 117(7): 1531–1539. https://doi.org/10.1002/jso.25027
Ahn, K. S., Kang, K. J., Kim, Y. H., Kim, T. S., Song, B. I., Kim, H. W., O’Brien, D., Roberts, L. R., Lee, J. W., Won, K. S. Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma. Annals of Surgical Treatment and Research, 2019, 96(4): 153. https://doi.org/10.4174/astr.2019.96.4.153
Lee, H. S., Han, D. H., Cho, K., Park, S. B., Kim, C., Leem, G., Jung, D. E., Kwon, S. S., Kim, C. H., Jo, J. H. et al. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping. Nature Communications, 2023, 14: 237. https://doi.org/10.1038/s41467-023-35896-4
The articles published in this open access journal are distributed under the termsof the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution andreproduction in any medium, provided the original work is properly cited.
京公网安备11010802044758号